USPH Stock Analysis: U.S. Physical Therapy | NYSE

Physical Therapy, Orthopedic Care, Sports Injury, Industrial Injury Prevention

Total Rating 40

Safety 77

Buy Signal -0.35

Medical Care Facilities
Industry Rotation: -11.9

Market Cap: 1.16B
Avg Turnover: 17.7M

Risk 3d forecast

Volatility34.4%

VaR 5^th Pctl5.66%

VaR vs Median-0.07%

Reward TTM

Sharpe Ratio-0.16

Rel. Str. IBD47.6

Rel. Str. Peer Group52.8

Character TTM

Beta0.720

Beta Downside0.619

Hurst Exponent0.532

Drawdowns 3y

Max DD45.39%

CAGR/Max DD-0.14

CAGR/Mean DD-0.29

EPS (Earnings per Share)

EPS CAGR: 0.64%
EPS Trend: 21.8%

Last SUE: -1.10
Qual. Beats: -1

Revenue

Rev. CAGR: 8.51%
Rev. Trend: 93.8%

Last SUE: 0.14
Qual. Beats: 0

Warnings

P/E Ratio 487.5

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +0.6% 22

Feb -1.3% 21

Mar -3.4% 28

Apr +3.8% 31

May -0.9% 5

Jun +4.6% 9

Jul +2.2% 30

Aug -0.0% 5

Sep -4.1% 45

Oct -3.8% 16

Nov +5.6% 12

Dec +1.7% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: USPH U.S. Physical Therapy

U.S. Physical Therapy, Inc. (USPH) operates and manages outpatient physical therapy clinics across the United States, operating through two reportable segments: Physical Therapy Operations and Industrial Injury Prevention Services.

The Physical Therapy Operations segment delivers pre- and post-operative care, orthopedic rehabilitation, sports injury treatment, preventative care, workers compensation rehabilitation, and neurological injury treatment to patients in a clinic-based outpatient setting.

The Industrial Injury Prevention Services segment contracts with large employers-including Fortune 500 companies, insurers, and their contractors-to provide onsite injury prevention, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments, delivered by physical therapists and certified athletic trainers.

Listed on the NYSE and classified within the GICS Health Care Facilities sub-industry, USPH represents a small-cap healthcare services provider, headquartered in Houston, Texas, with its founding year traced to 1990. The outpatient rehabilitation model relies on referral-based patient volumes from physicians, employers, and insurance carriers, while the industrial segment generates revenue through direct employer contracts.

Headlines to Watch Out For

Industrial Injury Prevention segment outpaces core clinic growth
Patient visit volumes soften on weaker elective procedure referrals
Rising therapist wages and labor costs pressure operating margins

Piotroski VR-10 (Strict) 4.0

Net Income: -6.03m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.03 > 1.0
NWC/Revenue: 3.82% < 20% (prev 3.26%; Δ 0.56% < -1%)
CFO/TA 0.07 > 3% & CFO 83.0m > Net Income -6.03m
Net Debt (526.7m) to EBITDA (100.3m): 5.25 < 3
Current Ratio: 1.27 > 1.5 & < 3
Outstanding Shares: last quarter (15.1m) vs 12m ago -0.84% < -2%
Gross Margin: 19.17% > 18% (prev 20.37%; Δ -1.20% > 0.5%)
Asset Turnover: 64.16% > 50% (prev 56.39%; Δ 7.77% > 0%)
Interest Coverage Ratio: 7.27 > 6 (EBIT TTM 78.2m / Interest Expense TTM 10.8m)

Altman Z'' 2.12

A: 0.02 (Total Current Assets 139.7m - Total Current Liabilities 109.9m) / Total Assets 1.25b
B: 0.17 (Retained Earnings 213.4m / Total Assets 1.25b)
C: 0.06 (EBIT TTM 78.2m / Avg Total Assets 1.21b)
D: 0.93 (Book Value of Equity 448.7m / Total Liabilities 482.2m)
Altman-Z'' = 2.12 = BBB

Beneish M -3.00

DSRI: 0.90 (Receivables 98.2m/93.4m, Revenue 779.1m/665.2m)
GMI: 1.06 (GM 20.37% / 19.17%)
AQI: 0.89 (AQ_t 0.66 / AQ_t-1 0.74)
SGI: 1.17 (Revenue 779.1m / 665.2m)
TATA: -0.07 (NI -6.03m - CFO 83.0m) / TA 1.25b)
Beneish M = -3.00 (Cap -4..+1) = AA

What is the price of USPH shares?

As of August 25, 2026, the stock is trading at USD 77.38 with a total of 171,046 shares traded. Over the past week, the price has changed by -0.82%, over one month by +4.37%, over three months by +25.32% and over the past year by -7.13%.

Current recommended Stop Loss: 73.60 (which is 4.9% or 1.3 ATR below the current price).

Is USPH a buy, sell or hold?

U.S. Physical Therapy has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy USPH.

StrongBuy: 2
Buy: 4
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the USPH price?

Analysts Target Price	95	22.8%

U.S. Physical Therapy (USPH) - Fundamental Data Overview as of 22 August 2026

Market Cap USD = 1.16b (1.16b USD * 1.0 USD.USD)
P/E Trailing = 487.5
P/E Forward = 28.8184
P/S = 1.4472
P/B = 2.6346
P/EG = 2.8804
Revenue TTM = 779.1m USD
EBIT TTM = 78.2m USD
EBITDA TTM = 100.3m USD
Long Term Debt = 215.5m USD (from longTermDebt, last quarter)
Short Term Debt = 47.4m USD (from shortTermDebt, last quarter)
Debt = 551.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 165.8m
Net Debt = 526.7m USD (calculated: Debt 551.6m - CCE 24.9m)
Enterprise Value = 1.69b USD (1.16b + Debt 551.6m - CCE 24.9m)
Interest Coverage Ratio = 7.27 (Ebit TTM 78.2m / Interest Expense TTM 10.8m)
EV/FCF = 26.39x (Enterprise Value 1.69b / FCF TTM 64.1m)
FCF Yield = 3.79% (FCF TTM 64.1m / Enterprise Value 1.69b)
FCF Margin = 8.22% (FCF TTM 64.1m / Revenue TTM 779.1m)
Net Margin = -0.77% (Net Income TTM -6.03m / Revenue TTM 779.1m)
Gross Margin = 19.17% ((Revenue TTM 779.1m - Cost of Revenue TTM 629.7m) / Revenue TTM)
Gross Margin QoQ = 19.59% (prev 14.47%)
Tobins Q-Ratio = 1.35 (Enterprise Value 1.69b / Total Assets 1.25b)
Interest Expense / Debt = 1.95% (Interest Expense 10.8m / Debt 551.6m)
Taxrate = 26.06% (17.6m / 67.4m)
NOPAT = 57.8m (EBIT 78.2m * (1 - 26.06%))
Current Ratio = 1.27 (Total Current Assets 139.7m / Total Current Liabilities 109.9m)
Debt / Equity = 1.23 (Debt 551.6m / totalStockholderEquity, last quarter 448.7m)
Debt / EBITDA = 5.25 (Net Debt 526.7m / EBITDA 100.3m)
Debt / FCF = 8.22 (Net Debt 526.7m / FCF TTM 64.1m)
Total Stockholder Equity = 474.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.50% (Net Income -6.03m / Total Assets 1.25b)
RoE = -1.27% (Net Income TTM -6.03m / Total Stockholder Equity 474.4m)
RoCE = 11.34% (EBIT 78.2m / Capital Employed (Equity 474.4m + L.T.Debt 215.5m))
RoIC = 4.98% (NOPAT 57.8m / Invested Capital 1.16b)
WACC = 6.24% (E(1.16b)/V(1.72b) * Re(8.51%) + D(551.6m)/V(1.72b) * Rd(1.95%) * (1-Tc(0.26)))
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 59.24 | Cagr: 0.16%
[DCF] Terminal Value 76.11% ; FCFF base≈62.8m ; Y1≈65.8m ; Y5≈75.9m
[DCF] Fair Price = 43.13 (EV 1.17b - Net Debt 526.7m = Equity 643.7m / Shares 14.9m; r=8.35% [WACC [floored]]; 5y FCF grow 5.26% → 2.50% )
EPS Correlation: 21.82 | EPS CAGR: 0.64% | SUE: -1.10 | # QB: -1
Revenue Correlation: 93.85 | Revenue CAGR: 8.51% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.75 | Chg30d=-5.98% | Revisions=+25% | Analysts=7
EPS current Year (2026-12-31): EPS=2.89 | Chg30d=-1.08% | Revisions=-40% | GrowthEPS=+10.0% | GrowthRev=+8.3%
EPS next Year (2027-12-31): EPS=3.38 | Chg30d=-0.89% | Revisions=+0% | GrowthEPS=+16.9% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: -12% (up=2, down=3)